Key result
Echocardiographic disease progression after cardiac resynchronization therapy was associated with a higher risk of death, VAD implantation, or heart transplantation compared to nonprogression.
Why the study?
The long-term outcomes and prognosis of heart failure patients termed nonprogressors, who show neither amelioration nor worsening of echocardiographic parameters after CRT implantation, remained poorly characterized.
Does echocardiographic nonprogression after CRT implantation improve long-term outcomes compared to progression in heart failure patients?
Cohort (n=391)
No
Does echocardiographic nonprogression after CRT implantation improve long-term outcomes compared to progression in heart failure patients?
Answers are grounded in this paper and cite their sources.
Heart failure patients who are 'nonprogressors' (ΔLVEF ±5%) after CRT implantation have significantly better long-term survival compared to progressors, indicating nonprogression is a form of positive response.
BACKGROUND: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in selected heart failure patients. A distinct subpopulation (so-called "nonprogressors") of patients shows neither amelioration nor worsening of echocardiographic parameters after CRT implantation. OBJECTIVES: The authors sought to investigate the long-term outcomes and prognosis of a distinct subpopulation of heart failure patients termed "nonprogressors," after CRT implantation. METHODS: Retrospective single-center cohort analysis of 391 patients after CRT implantation. Based on echocardiography, patients were categorized into "super-responders" (Δ left ventricular ejection fraction [LVEF] >15% compared to baseline), "responders" (ΔLVEF >5% compared to baseline), "nonprogressors" (ΔLVEF ±5% compared to baseline), and "progressors" (ΔLVEF <-5% compared to baseline). The primary composite outcome was all-cause death, implantation of a ventricular assist device, or heart transplantation. Statistics included univariable and multivariable Cox proportional hazard regression analysis and Kaplan-Meier survival curves to explore outcome data. RESULTS: A total of 391 patients (23% female, mean age 65 years, mean baseline LVEF 27%) were included. Postimplantation echocardiograms were performed after a mean of 37 months after CRT implantation. A total of 134 patients (34%) were nonprogressors. After a mean follow-up of another 57 months, progressors were significantly more likely to reach the composite endpoint of death, ventricular assist device implantation, or heart transplantation compared to nonprogressors (adjusted HR: 2.26 [95% CI: 1.35-3.78]; P = 0.002). Patients with positive echocardiographic response and super-response fared significantly better compared to nonprogressors. CONCLUSIONS: Nonprogressors form a relevant, to date poorly characterized group of CRT patients, whose long-term survival is significantly better compared to progressors or negative responders.
No takes yet. Share an insight, caveat, or question.
Trenson et al. (2025) conducted a cohort in Heart failure (n=391). Echocardiographic disease progression (ΔLVEF < -5%) vs. Echocardiographic nonprogression (ΔLVEF ±5%) was evaluated on Composite of all-cause death, ventricular assist device implantation, or heart transplantation (aHR 2.26, 95% CI 1.35-3.78, p=0.002). Echocardiographic disease progression after cardiac resynchronization therapy was associated with a higher risk of death, VAD implantation, or heart transplantation compared to nonprogression.
Synapse has enriched 10 related papers. Consider them for comparative context: